Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04929015 · ClinicalTrials.gov registry record · NA
Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)
A NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT04929015: Recruiting NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma, sponsored by Rutgers, The State University of New Jersey.
NCT04929015 is a NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 30 participants, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04929015, a NA study of Peritoneal Carcinomatosis and Liver and Intrahepatic Bile Duct Carcinoma, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and function. Everyone is born with the same DNA in all our cells throughout our body. Sometimes, some of the cells in the body develop abnormalities in the DNA that cause those cells to grow abnormally and uncontrollably. Cancer occurs when there is abnormal and uncontrolled growth of cells. The DNA in cancer cells is therefore different from the DNA someone is born with. The Signatera ctDNA assay is a laboratory test that takes tumor (cancer) tissue and evaluates it for unique tumor DNA. This evaluation is used to create a report (otherwise known as an assay) personalized to each person's cancer. The personalized assay creates a personalized blood test to detect the level of abnormal DNA from the cancer that may be circulating in the body. Once this personalized blood assay is designed, it may be used to monitor a person's blood for the presence of ctDNA, which will indicate the presence or absence of cancer over time, even after treatment.
Conditions Studied
Interventions
- OTHER Electronic Health Record Review
- PROCEDURE Biospecimen Collection - blood and tissue sample collection
Study Locations (2)
New Jersey
- RWJBarnabas Health - Cooperman Barnabas, Livingston - Livingston
- Rutgers Cancer Institute of New Jersey - New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2024-11-01 |
| Phase | NA |
What NCT04929015 shows while recruiting
NCT04929015 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 58-participant average among 14 other Peritoneal Carcinomatosis trials with a reported enrollment target (48% lower).
The record links to 7 conditions, with Peritoneal Carcinomatosis appearing as the primary indexed condition, and to 2 interventions - of which Electronic Health Record Review is the first listed.
NCT04929015 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04929015 about?
NCT04929015 is a clinical study titled "Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)". This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and fun...
What is the current status of trial NCT04929015?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-04-29. Estimated completion is 2024-11-01.
What conditions does trial NCT04929015 study?
This clinical trial studies the following conditions: Peritoneal Carcinomatosis, Liver and Intrahepatic Bile Duct Carcinoma, Digestive System Neoplasm, Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage.
What interventions are being tested in trial NCT04929015?
The interventions under investigation include: Electronic Health Record Review (OTHER), Biospecimen Collection - blood and tissue sample collection (PROCEDURE).
Who is sponsoring clinical trial NCT04929015?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04929015 being conducted?
This trial has 2 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Carcinomatosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04929015's enrollment target sits among peer trials
30 7th of 14 higher than 7 of 14 other Peritoneal Carcinomatosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peritoneal Carcinomatosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis
RECRUITING · NA
-
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
RECRUITING · Phase 1
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
RECRUITING · Phase 2
-
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
RECRUITING · Phase 2
-
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI